Please assess the completion status of the following clinical trial:

Trial Title: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization;~* Be at least 70% compliant to their anti-hypertensive medication regimen;~* Has a seated BP ≥ 130/80 mmHg;~* Agrees to comply with the contraception and reproduction restrictions of the study; and~* Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines.~Exclusion Criteria:~* Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;~* Has a body mass index (BMI) \> 40 kg/m2;~* Has an upper arm circumference \< 7 or \> 17 inches;~* Has been on night shifts at any time during the 4 weeks before Screening;~* Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);~* Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;~* Is not willing or not able to discontinue taking a potassium supplement;~* Has documented estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73m2~* Has known and documented New York Heart Association stage III or IV chronic heart failure~* Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;~* Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;~* Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;~* Has chronic permanent atrial fibrillation;~* Has uncontrolled diabetes with glycosylated hemoglobin \> 9.5% at Screening;~* Has planned dialysis or kidney transplant during the course of this study;~* Potassium \< 3.5 mEq/L;~* Potassium \> 5.0 mEq/L;~* Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;~* Has typical consumption of ≥14 alcoholic drinks weekly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CIN-107 0.5mg (Type: EXPERIMENTAL): Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
- CIN-107 1mg (Type: EXPERIMENTAL): Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
- CIN-107 2mg (Type: EXPERIMENTAL): Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).